Abstract 4458
Background
INT230-6 is a formulation of cisplatin and vinblastine with an amphiphillic penetration enhancer to improve dispersion and diffusion into cancer cells. This is the first product designed for selective delivery into tumors with the potential to deliver high payload levels directly into cancer cells while sparing healthy cells. In colon 26 animal models, injection into a sentinel lesion led to tumor necrosis, recruitment of dendritic cells into the tumor and activation of CD4 and CD8 T-cells. Injected tumors experienced high rates of complete response (up to 80%). Importantly, untreated lesions distal to the injection site also responded. Efficacy was synergistic when combined with checkpoint inhibitors.
Methods
Initial cohort enrolled subjects with advanced solid tumors with superficial lesions amenable to local injection. INT230-6 was administered intratumorally at a ratio of 1ml for each 4 cubic cm of tumor volume, once each month for a total of 5 cycles. Both the maximal dose into one tumor and the total dose (over multiple lesions) could be escalated on repeat cycles if no DLTs. Patients were monitored for safety weekly. Pharmacokinetic(Pk) samples and peripheral blood were collected for flow cytometry and circulating cytokines. Subsequent cohorts of twice monthly injections into superficial tumors and monthly injection into deep tumors commenced after comprehensive review of safety data in superficial tumors.
Results
Thirteen subjects were treated with either melanoma, SCC, ovarian, chordoma, cholangiocarcinoma or H&N into single or multiple lesions. Pk analysis revealed negligible amounts of reduced platinum and vinblastine in blood, suggesting retention in the tumor compartments. No DLTs or drug related SAEs were reported. The most frequent adverse event was grade 1 or 2 injection site pain, or other local symptom (infection or blister). Subjectively, some injected lesions were noted to change as soon as 1 week with flattening and areas of necrosis.
Conclusions
INT230-6 was safe when administered locally to tumors at doses given. Updated results will be presented including biomarker and response data. Additional cohorts including higher drug concentrations and combination with an anti-PD1 antibody.
Clinical trial identification
NCT:03058289.
Legal entity responsible for the study
Ian B. Walters, MD.
Funding
Intensity Therapeutics.
Editorial Acknowledgement
Disclosure
A. El-Khoeuiry, L.L. Siu, N. Azad, A.J. Olszanski: Funding to institutions: Intensity Therapeutics. I.B. Walters: Employee and stockholder: Intensity Therapeutics. L. Bender: Founder and CEO of Intensity Therapeutics, named on the patents, stock holder and employee of the company which manufactures the product being studied. L. Kamen: Consultant and stock owner: Intensity therapeutics.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract